Group 4G: HER2-Low Breast Cancer
Thursday, Dec 15
10:00 am – 11:30 am Eastern Time (US/New York)
Poster #P1-11-01:
Trastuzumab deruxtecan vs treatment of physician’s choice in patients with HER2-low unresectable and/or metastatic breast cancer: Subgroup analyses from DESTINY-Breast04
Poster #HER2-04:
Prevalence of HER2-low among stage I-III and metastatic breast cancer patients and their outcomes by HER2 status
Mentor: Amy Beumer, Ph.D.
Amy was diagnosed with stage I breast cancer in 2017 and metastatic in 2020. In her previous life she was a biology professor teaching various microbiology and introductory biology courses as well as conducting research in drinking water microbiology and team learning. Currently, she is upping her knowledge of cancer research, advocating, and getting as much traveling, hiking, reading, gardening and time with friends and family in as possible.Twitter: @amybeumer
Scientist: Ariella Hanker, Ph.D.
Ariella is an assistant professor in the Simmons Comprehensive Cancer Center at UT Southwestern Medical Center in Dallas, TX. She pursued postdoctoral training in the laboratory of Dr. Carlos Arteaga at Vanderbilt University Medical Center. Her postdoctoral studies focused on mechanisms of resistance to HER2-targeted therapy in HER2+ breast cancer. More recently, she identified the HER2 gatekeeper mutation as a mechanism of resistance to HER2-targeted therapy in HER2-mutant breast cancer.
Her lab’s current work is focused on 1) therapeutic targeting of genetic alterations that drive metastatic breast cancer, and 2) delineating mechanisms of resistance to breast cancer targeted therapies, including HER2 inhibitors, antiestrogens, PI3K/AKT inhibitors, and CDK4/6 inhibitors. Her research program is supported by grants from the National Cancer Institute and the Breast Cancer Research Foundation. Ariella also co-leads the Breast Organoid Working Group. In her spare time, Ariella enjoys traveling and exploring Texas with her husband and 3 children.
Twitter: @AriellaHanker
